Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.27), $0.11 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $74.6 million versus the consensus estimate of $81.78 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.